Suppr超能文献

微生物在L-抗坏血酸生产中的应用:现状与未来展望。

The use of micro-organisms for L-ascorbic acid production: current status and future perspectives.

作者信息

Hancock R D, Viola R

机构信息

Division of Biochemistry and Cell Biology, Scottish Crop Research Institute, Invergowrie, Dundee, UK.

出版信息

Appl Microbiol Biotechnol. 2001 Sep;56(5-6):567-76. doi: 10.1007/s002530100723.

Abstract

L-Ascorbic acid (L-AA) has been industrially produced for around 60 years in a primarily chemical process utilising D-glucose (D-glc) as starting material. Current world production is estimated at approximately 80,000 tonnes per annum with a worldwide market in excess of U.S. $600 million. We present a brief overview of research geared to exploiting micro-organisms for the industrial production of vitamin C, with emphasis on recent approaches using genetically engineered bacterial strains. We also discuss the potential for direct production of L-AA exploiting novel biochemical pathways with particular reference to yeast fermentations. The potential advantages of these novel approaches over current chemical and biotechnological processes are outlined.

摘要

L-抗坏血酸(L-AA)以D-葡萄糖(D-glc)为起始原料,通过主要的化学过程进行工业化生产已有约60年历史。目前全球年产量估计约为80000吨,全球市场超过6亿美元。我们简要概述了利用微生物进行维生素C工业化生产的研究,重点是使用基因工程细菌菌株的最新方法。我们还讨论了利用新型生化途径直接生产L-AA的潜力,特别是涉及酵母发酵。概述了这些新方法相对于当前化学和生物技术过程的潜在优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验